| GTO ID | GTC3994 |
| Trial ID | NCT02798406 |
| Disease | Brain Glioma |
| Altered gene | E1A|RGD |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | DNA oncolytic virus |
| Treatment | Ad5-Delta 24RGD|DNX-2401|tasadenoturev |
| Co-treatment | pembrolizumab |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192) |
| Year | 2016 |
| Country | United States|Canada |
| Company sponsor | DNAtrix, Inc. |
| Other ID(s) | 2401BT-002P |
| Vector information | |||||||||||||
|
|||||||||||||
| Cohort1: dose level 1 | |||||||||
|
|||||||||
| Cohort2: dose level 2 | |||||||||
|
|||||||||
| Cohort3: dose level 3 | |||||||||
|
|||||||||